Plain-language summary, compiled from the cited regulatory records
Erythromycin is an antiinfective medication used for the topical treatment of acne vulgaris [1]. It belongs to the drug class of antiinfectives for the treatment of acne [1].
This active ingredient is available under various brand names, including Ery [1]. In the past 12 months, there have been 824 adverse event reports associated with erythromycin [2]. The most frequently reported adverse events include eye pain, fatigue, off-label use, diarrhea, and joint pain (arthralgia) [2].
This is not medical advice. Consult a qualified healthcare professional.
GBOfficial regulatory label· revised May 22, 2026[1]
For the prophylaxis and treatment of infections caused by erythromycin sensitive organisms. Erythromycin is effective in the treatment of a great variety a clinical infections. 1.
Upper respiratory tract infection:
Tonsillitis, peritonsillar abscess, pharyngitis, laryngitis, sinusitis, secondary infections in clods and influenza. 2.
Lower respiratory tract infections:
Tracheitis, acute and chronic bronchitis, pneumonia, bronchiectasis. 3.
Oral infections:
Gingivitis, Vincent’s angina. 4.
Eye infections:
Blepharitis. 5. Ear infections: otitis media and otitis externa, mastoiditis. 6. Skin and soft tissue infections: boils and carbuncles, paronychia, abscesses, acne, impetigo, cellulitis, erysipelas. 7. Prophylazis: pre- and post-operative, trauma, burns, rheumatic fever.
USUnited States· FDA
8 products
Uses
USOfficial regulatory label· revised April 21, 2026[2]
INDICATIONS AND USAGE
To reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin tablets, USP and other antibacterial drugs, erythromycin tablets, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.
When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Erythromycin tablet, USP are indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes ; Streptococcus pneumoniae ; Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H.
CACanada· Health Canada
7 products
Who should not take it
CAOfficial regulatory label· Contraindications· revised March 22, 2025[3]
Erythromycin and its derivatives should not be used in patients with known hypersensitivity to these drugs or any ingredient in the formulations or with infections that are resistant to the drug (primarily certain Staphylococci organisms).
ADVERSE EFFECTS Serious allergic reactions to erythromycin have been extremely infrequent. Mild allergic reactions, such as urticaria and morbilliform skin rashes have occurred. Should a patient demonstrate signs of hypersensitivity, administer appropriate countermeasures such as epinephrine, corticosteroid and antihistamines, and withdraw the antibiotic.
DOSAGE AND ADMINISTRATION In the treatment of external ocular infections, apply the ointment directly to the infected structure one or more times daily, depending on the severity of the infection. 5 to 1 cm in length should be instilled into each conjunctival sac.
Drug interactions
Known interactions involving Erythromycin. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 600. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
[2]FDA DailyMed · 0c05e1f7-a3d4-8e… · revised April 21, 2026 [PDF]
[3]Health Canada (DPD) · 02326663 · revised March 22, 2025
[4]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.
Erythromycin is active against a wide range of gram-positive staphylococci, pneumococci and streptococci, Meningococci, Mycoplasma, L-forms, Haemophilus influenzae, agents causing trachoma and lymphogranuloma vernereum, Chlamydia, clostridia, coryneacteria, Neisseria, Treponema pallidum and Bordetella.
How to take
GBOfficial regulatory label· revised May 22, 2026[1]
Adults: 1g to 2g/day erythromycin activity divided into 6, 8 or 12 hourly doses. May be increased to up to 4g daily in divided doses in severe infections. Tablets should be taken before and with meals.
Children:
Normally use Erythromycin Suspension. If tablets are used calculate dose on basis of 30mg erythromycin activity/kg/day in divided doses. In severe infections this may be raised to 50mg/kg/day in divided doses.
This is not medical advice. Consult a qualified healthcare professional.
Side effects & warnings
GBOfficial regulatory label· Adverse reactions· revised May 22, 2026[1]
Blood and lymphatic system disorders:
Eosinophilia. Cardiac disorders QTc interval prolongation, torsades de pointes, palpitations, and cardiac rhythm disorders including ventricular tachyarrhythmias. Ear and labyrinth disorders Deafness, tinnitus. There have been isolated reports of reversible hearing loss occurring chiefly in patients with renal insufficiency or high doses.
Gastrointestinal disorders The most frequent side effects of oral erythromycin are gastrointestinal and are dose- related.
The following have been reported:
Upper abdominal discomfort, nausea, vomiting, diarrhoea, pancreatitis, anorexia, infantile hypertrophic pyloric stenosis. 4). General disorders and administration site conditions Chest pain, fever, malaise. 4). Immune system disorders Allergic reactions ranging from urticaria and mild skin eruptions to anaphylaxis have occurred.
Investigations Increased liver enzyme values. Nervous system disorders There have been isolated reports of transient central nervous system side effects including confusion, seizures and vertigo; however, a cause and effect relationship has not been established.
Not known (frequency cannot be estimated from the available data): acute generalised exanthematous pustulosis (AGEP) Vascular disorders Hypotension. The rare possibility of super infection caused by overgrowth of non-susceptible bacteria or fungi should be considered during prolonged or repeated therapy, especially when other antibacterial agents are simultaneously employed.
Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
GBOfficial regulatory label· Warnings and precautions· revised May 22, 2026[1]
Erythromycin is excreted principally by the liver, so caution should be exercised in administering the antibiotic to patients with impaired hepatic function or concomitantly receiving potentially hepatotoxic agents. Hepatic dysfunction including increased liver enzymes and/or cholestatic hepatitis, with or without jaundice, has been infrequently reported with erythromycin.
This product should not be used in patients with porphyria. 8). Clostridium difficile-associated diarrhoea (CDAD) has been reported with use of nearly all antibacterial agents including erythromycin, and may range in severity from mild diarrhoea to fatal colitis.
Treatment with antibacterial agents alters the normal flora of the colon, which may lead to overgrowth of C. difficile. CDAD must be considered in all patients who present with diarrhoea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.
Patients receiving erythromycin concurrently with drugs which can cause prolongation of the QT interval should be carefully monitored. 5). There have been reports suggesting erythromycin does not reach the foetus in adequate concentrations to prevent congenital syphilis.
Infants born to women treated during pregnancy with oral erythromycin for early syphilis should be treated with an appropriate penicillin regimen. There have been reports that erythromycin may aggravate the weakness of patients with myasthenia gravis.
Erythromycin interferes with the fluorometric determination of urinary catecholamines. Rhabdomyolysis with or without renal impairment has been reported in seriously ill patients receiving erythromycin concomitantly with statins. There have been reports of infantile hypertrophic pyloric stenosis (IHPS) occurring in infants following erythromycin therapy.
In one cohort of 157 newborns who were given erythromycin for pertussis prophylaxis, seven neonates (5%) developed symptoms of non- bilious vomiting or irritability with feeding and were subsequently diagnosed as having IHPS requiring surgical pyloromyotomy.
Since erythromycin may be used in the treatment of conditions in infants which are associated with significant mortality or morbidity (such as pertussis or chlamydia), the benefit of erythromycin therapy needs to be weighed against the potential risk of developing IHPS.
This is not medical advice. Consult a qualified healthcare professional.
Who should not take it
GBOfficial regulatory label· Contraindications· revised May 22, 2026[1]
1. Erythromycin is contraindicated in patients taking simvastatin, tolterodine, mizolastine, amisulpride, astemizole, terfenadine, domperidone, cisapride or pimozide. Erythromycin is contraindicated with ergotamine and dihydroergotamine.
5).
This is not medical advice. Consult a qualified healthcare professional.
influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). ) Lower respiratory tract infections of mild to moderate severity caused by Streptococcus pyogenes or Streptococcus pneumoniae . Listeriosis caused by Listeria monocytogenes .
Respiratory tract infections due to Mycoplasma pneumoniae . Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment).
Pertussis (whooping cough) caused by Bordetella pertussis . Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals, rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals.
Diphtheria:
Infections due to Corynebacterium diphtheriae , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers.
Erythrasma:
In the treatment of infections due to Corynebacterium minutissimum . Intestinal amebiasis caused by Entamoeba histolytica (oral erythromycins only). Extraenteric amebiasis requires treatment with other agents. V. (erythromycin lactobionate for injection, USP) followed by erythromycin base orally, as an alternative drug treatment of acute pelvic inflammatory disease caused by N.
gonorrhoeae in female patients with a history of sensitivity to penicillin. Patients should have a serologic test for syphilis before receiving erythromycin as treatment of gonorrhea and a follow-up serologic test for syphilis after 3 months.
Erythromycins are indicated for treatment of the following infections caused by Chlamydia trachomatis : conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections during pregnancy. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of uncomplicated urethral, endocervical, or rectal infections in adults due to Chlamydia trachomatis .
3 When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of nongonococcal urethritis caused by Ureaplasma urealyticum . 3 Primary syphilis caused by Treponema pallidum . Erythromycin (oral forms only) is an alternative choice of treatment for primary syphilis in patients allergic to the penicillins.
In treatment of primary syphilis, spinal fluid should be examined before treatment and as part of the follow-up after therapy. Legionnaires’ Disease caused by Legionella pneumophila . Although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating Legionnaires’ Disease.
, tonsillitis, or pharyngitis). 1 Erythromycin is indicated for the treatment of penicillin-allergic patients. The therapeutic dose should be administered for ten days. Prevention of Recurrent Attacks of Rheumatic Fever Penicillin or sulfonamides are considered by the American Heart Association to be the drugs of choice in the prevention of recurrent attacks of rheumatic fever.
In patients who are allergic to penicillin and sulfonamides, oral erythromycin is recommended by the American Heart Association in the long-term prophylaxis of streptococcal pharyngitis (for the prevention of recurrent attacks of rheumatic fever).
1
How to take
USOfficial regulatory label· revised April 21, 2026[2]
DOSAGE AND ADMINISTRATION
In most patients, erythromycin tablets are well absorbed and may be dosed orally without regard to meals. However optimal blood levels are obtained when erythromycin tablets are given in the fasting state (at least ½ hour and preferably 2 hours before meals).
Adults The usual dosage of erythromycin tablets is one 250 mg tablet four times daily in equally spaced doses or one 500 mg tablet every 12 hours. Dosage may be increased up to 4 g per day according to the severity of the infection.
However, twice-a-day dosing is not recommended when doses larger than 1g daily are administered. Children Age, weight, and severity of the infection are important factors in determining the proper dosage. The usual dosage is 30 to 50 mg/kg/day, in equally divided doses.
For more severe infections this dosage may be doubled but should not exceed 4 g per day. , tonsillitis or pharyngitis), the therapeutic dosage of erythromycin should be administered for at least ten days. The American Heart Association suggests a dosage of 250 mg of erythromycin orally, twice a day in long-term prophylaxis of streptococcal upper respiratory tract infections for the prevention of recurring attacks of rheumatic fever in patients allergic to penicillin and sulfonamides.
1 Conjunctivitis of the Newborn Caused by Chlamydia trachomatis Oral erythromycin suspension 50 mg/kg/day in 4 divided doses for at least 2 weeks. 3 Pneumonia of Infancy Caused by Chlamydia trachomatis Although the optimal duration of therapy has not been established, the recommended therapy is oral erythromycin suspension 50 mg/kg/day in 4 divided doses for at least 3 weeks.
Urogenital Infections During Pregnancy Due to Chlamydia trachomatis Although the optimal dose and duration of therapy have not been established, the suggested treatment is 500 mg of erythromycin by mouth four times a day on an empty stomach for at least 7 days.
For women who cannot tolerate this regimen, a decreased dose of one erythromycin 500 mg tablet orally every 12 hours or 250 mg by mouth four times a day should be used for at least 14 days. 3 For adults with uncomplicated urethral, endocervical, or rectal infections caused by Chlamyia trachomatis, when tetracycline is contraindicated or not tolerated 500 mg of erythromycin by mouth four times a day for at least 7 days.
3 For patients with nongonococcal urethritis caused by Ureaplasma urealyticum when tetracycline is contraindicated or not tolerated 500 mg of erythromycin by mouth four times a day for at least seven days. 3 Primary syphilis 30 to 40 g given in divided doses over a period of 10 to 15 days.
Acute Pelvic Inflammatory Disease Caused by N. V. (erythromycin lactobionate for injection, USP) every 6 hours for 3 days, followed by 500 mg of erythromycin base orally every 12 hours for 7 days. Intestinal Amebiasis Adults 500 mg every 12 hours or 250 mg every 6 hours for 10 to 14 days.
Children 30 to 50 mg/kg/day in divided doses for 10 to 14 days. Pertussis Although optimal dosage and duration have not been established, doses of erythromycin utilized in reported clinical studies were 40 to 50 mg/kg/day, given in divided doses for 5 to 14 days.
Legionnaires’ Disease Although optimal dosage has not been established, doses utilized in reported clinical data were 1 to 4 g daily in divided doses.
This is not medical advice. Consult a qualified healthcare professional.
Most-reported reactions to the US regulator (12 mo to June 4, 2026): 824 reports total. [4]
Eye Pain 95
Fatigue 84
Off Label Use 72
Diarrhoea 68
Arthralgia 64
Drug Ineffective 62
Headache 58
Dyspnoea 55
Abdominal Discomfort 53
Abdominal Pain 51
Asthma 50
Alopecia 49
Side effects & warnings
USOfficial regulatory label· Adverse reactions· revised April 21, 2026[2]
ADVERSE REACTIONS
The most frequent side effects of oral erythromycin preparations are gastrointestinal and are dose-related. They include nausea, vomiting, abdominal pain, diarrhea and anorexia. Symptoms of hepatitis, hepatic dysfunction and/or abnormal liver function test results may occur.
) Onset of pseudomembranous colitis symptoms may occur during or after antibacterial treatment. ) Erythromycin has been associated with QT prolongation and ventricular arrhythmias, including ventricular tachycardia and torsades de pointes.
) Allergic reactions ranging from urticaria to anaphylaxis have occurred. Skin reactions ranging from mild eruptions to erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis have been reported rarely. There have been reports of interstitial nephritis coincident with erythromycin use.
There have been rare reports of pancreatitis and convulsions. There have been isolated reports of reversible hearing loss occurring chiefly in patients with renal insufficiency and in patients receiving high doses of erythromycin.
USOfficial regulatory label· Warnings and precautions· revised April 21, 2026[2]
WARNINGS
Hepatotoxicity There have been reports of hepatic dysfunction, including increased liver enzymes, and hepatocellular and/or cholestatic hepatitis, with or without jaundice, occurring in patients receiving oral erythromycin products.
QT Prolongation Erythromycin has been associated with prolongation of the QT interval and infrequent cases of arrhythmia. Cases of torsades de pointes have been spontaneously reported during postmarketing surveillance in patients receiving erythromycin.
Fatalities have been reported. Erythromycin should be avoided in patients with known prolongation of the QT interval, patients with ongoing proarrhythmic conditions such as uncorrected hypokalemia or hypomagnesemia, clinically significant bradycardia, and in patients receiving Class IA (quinidine, procainamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents.
Elderly patients may be more susceptible to drug-associated effects on the QT interval. Syphilis in Pregnancy There have been reports suggesting that erythromycin does not reach the fetus in adequate concentration to prevent congenital syphilis.
Infants born to women treated during pregnancy with oral erythromycin for early syphilis should be treated with an appropriate penicillin regimen. Clostridium-difficile Associated Diarrhea Clostridium difficile associated diarrhea (CDAD) has been reported with the use of nearly all antibacterial agents, including Erythromycin Tablets, and may range in severity from mild diarrhea to fatal colitis.
Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile . C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy.
CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.
If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile , and surgical evaluation should be instituted as clinically indicated.
Drug Interactions Serious adverse reactions have been reported in patients taking erythromycin concomitantly with CYP3A4 substrates. , verapamil, amlodipine, diltiazem) (see PRECAUTIONS – Drug Interactions ). There have been post-marketing reports of colchicine toxicity with concomitant use of erythromycin and colchicine.
This is not medical advice. Consult a qualified healthcare professional.
Who should not take it
USOfficial regulatory label· Contraindications· revised April 21, 2026[2]
CONTRAINDICATIONS
Erythromycin is contraindicated in patients with known hypersensitivity to this antibiotic. Erythromycin is contraindicated in patients taking terfenadine, astemizole, cisapride, pimozide, ergotamine, or dihydroergotamine. (See PRECAUTIONS – Drug Interactions ) Do not use erythromycin concomitantly with HMG CoA reductase inhibitors (statins) that are extensively metabolized by CYP 3A4 (lovastatin or simvastatin), due to the increased risk of myopathy, including rhabdomyolysis.
This is not medical advice. Consult a qualified healthcare professional.
The ointment should not be flushed from the eye following installation. A new tube should be used for each infant. Infants born by cesarean section as well as those delivered by vaginal route should receive prophylaxis.
AVAILABILITY Each 1 g of sterile ophthalmic ointment contains:
Erythromycin (base) 5 mg in a Mineral Oil and Petrolatum. 5 g and unit dose tubes of 1 g in boxes of 50. STORAGE CONDITIONS Store at room temperature (15-30oC). Protect from freezing. Keep tightly closed. ERYTHROMYCIN ophthalmic ointment USP Patient Medication Information Page 4 of 6 READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION Pr ERYTHROMYCIN Ophthalmic ointment USP Erythromycin ophthalmic ointment USP 5mg / g Read this carefully before you start taking ERYTHROMYCIN Ophthalmic ointment USP and each time you get a refill.
This leaflet is a summary and will not tell you everything about this drug. Talk to your healthcare professional about your medical condition and treatment and ask if there is any new information about ERYTHROMYCIN Ophthalmic ointment USP.
What is ERYTHROMYCIN Ophthalmic ointment USP used for? ERYTHROMYCIN Ophthalmic ointment USP is used to treat bacterial eye infections. Antibacterial drugs like ERYTHROMYCIN Ophthalmic ointment USP treat only bacterial infections.
They do not treat viral infections. Although you may feel better early in the treatment, ERYTHROMYCIN Ophthalmic ointment USP should be used exactly as directed. Misuse or overuse of ERYTHROMYCIN Ophthalmic ointment USP could lead to the growth of bacteria that will not be killed by ERYTHROMYCIN Ophthalmic ointment USP (resistance).
This means that ERYTHROMYCIN Ophthalmic ointment USP may not work for you in the future. Do not share your medicine. How does ERYTHROMYCIN Ophthalmic ointment USP work? ERYTHROMYCIN Ophthalmic ointment USP is an antibiotic. It works by killing or stopping the growth of the bacteria that cause your infection.
What are the ingredients in ERYTHROMYCIN Ophthalmic ointment USP?
Medicinal ingredients:
Erythromycin Non-medicinal ingredients: Mineral oil, Petrolatum ERYTHROMYCIN Ophthalmic ointment USP comes in the following dosage forms: Ointment: 5mg / g Do not use ERYTHROMYCIN Ophthalmic ointment USP if you: Are allergic to erythromycin or any other ingredients of ERYTHROMYCIN Ophthalmic ointment USP Have infections that are resistant to this medication (bacteria will not be killed).
To help avoid side effects and ensure proper use, talk to your healthcare professional before you take ERYTHROMYCIN Ophthalmic ointment USP. Talk about any health conditions or problems you may have. If you wear contact lenses, remove them before applying ERYTHROMYCIN Ophthalmic ointment USP.
These can be re-inserted 15 minutes after application of the ointment. Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines. ERYTHROMYCIN ophthalmic ointment USP Patient Medication Information Page 5 of 6 How to take ERYTHROMYCIN Ophthalmic ointment USP: Follow your doctor’s instruction carefully about how much ERYTHROMYCIN Ophthalmic ointment USP to apply and when to apply it.
Usual dose:
Apply the ointment directly into the affected eye(s) one or more times daily as directed by your doctor. Administration: 1. Wash hands before use. 2. Remove tube cap. 3. Tilt head up when looking in a mirror. 4. Gently pull down the lower eyelid until there is a “pocket” (see picture below).
5. 5-1 cm along in this pocket (see picture below). 6. Let go of the lower eyelid and close the eye for 30 seconds. 7. If you use ointment in both eyes, repeat the steps for the other eye. 8. To avoid contamination and injury, do not let the tip of the tube touch your eye.
9. If you are using another eye medicine, wait at least 15 minutes before applying the other medicine. 10. 5 g tube, close and tighten the cap. If you are using a 1 g single- use tube, discard tube after use.
Overdose:
In case of drug overdose, including ingestion, contact your healthcare professional, hospital emergency department or regional poison control centre, even if there are no symptoms.
Missed Dose:
If you forget to apply the ointment, simply apply it as soon as you remember. Then go back to the original schedule as directed by your doctor. Do not apply 2 doses to make up for the missed dose. What are possible side effects from using ERYTHROMYCIN Ophthalmic ointment USP?
These are not all the possible side effects you may feel when taking ERYTHROMYCIN Ophthalmic ointment USP. If you experience any side effects not listed here, contact your healthcare professional. ERYTHROMYCIN ophthalmic ointment USP Patient Medication Information Page 6 of 6 Side effects may include: Hives Skin rashes Serious side effects and what to do about them Symptom / effect Talk to your healthcare professional Stop taking drug and get immediate medical […]
This is not medical advice. Consult a qualified healthcare professional.
Parents should be informed to contact their physician if vomiting or irritability with feeding occurs. As with other macrolides, rare serious allergic reactions, including acute generalised exanthematous pustulosis (AGEP) have been reported.
If an allergic reaction occurs, the drug should be discontinued and appropriate therapy should be instituted. Physicians should be aware that reappearance of the allergic symptoms may occur when symptomatic therapy is discontinued. 5).
This interaction is potentially life-threatening, and may occur while using both drugs at their recommended doses (see PRECAUTIONS – Drug Interactions ). Rhabdomyolysis with or without renal impairment has been reported in seriously ill patients receiving erythromycin concomitantly with lovastatin.
Therefore, patients receiving concomitant lovastatin and erythromycin should be carefully monitored for creatine kinase (CK) and serum transaminase levels. )